Skip to main content
. 2023 Sep 21;17:1602. doi: 10.3332/ecancer.2023.1602

Table 1. Clinical–pathological details of patients included in the analysis.

Sex Males 22/30 (73%)
Females 8/30 (27%)
Tumour primary site Parotid gland 22/30 (73%)
Submandibular gland 5/30 (17%)
Sublingual and minor salivary glands 3/30 (10%)
Tumour histopathology ACC 11/30 (37%)
SDC 11/30 (37%)
MEC 7/30 (23%)
MASC 1/30 (3%)
Disease stage at presentation Recurrent advanced 17/30 (57%)
Upfront advanced 13/30 ( 43%)
Metastatic sites Lungs 17/30 (57%)
Bone 7/30 (23%)